Literature DB >> 3481325

Penetration of ofloxacin into bronchial secretions.

J Symonds1, M Bone, A Turner, A Javaid.   

Abstract

The penetration of ofloxacin into bronchial secretions was evaluated in 16 patients after administration of a single oral dose of ofloxacin 400mg. Bronchial secretions were aspirated at bronchoscopy after 1 to 6 hours and serum was collected simultaneously. Ofloxacin concentrations were measured by a microbiological assay method. Considerable individual variations in serum and bronchial aspirate concentrations were recorded: bronchial aspirate concentrations varied between 1.1 mg/L and 4.5 mg/L but exceeded 1.5 mg/L in 14 of 16 patients between 1 and 6 hours. The ratio between simultaneous mean bronchial aspirate and serum concentrations ranged between 0.53 in the second hour and 0.92 in the fourth hour. It is likely that inhibitory activity will be sustained over at least 6 hours against most potential respiratory pathogens including Haemophilus influenzae, Branhamella catarrhalis, Gram-negative bacilli, Staphylococcus aureus, Legionella pneumophila and Mycoplasma pneumoniae. Streptococcus pneumoniae and Pseudomonas aeruginosa may have minimal inhibitory concentration (MIC) values lower than ofloxacin concentrations achieved in bronchial secretions, although some isolates are less sensitive. Clinical studies should establish the relevance of pharmacokinetic data to respiratory infections caused by organisms of borderline susceptibility.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481325     DOI: 10.2165/00003495-198700341-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  11 in total

1.  Comparative in vitro activity of the new quinolone CI-934.

Authors:  L Verbist
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

Review 2.  Quinolones in chest infections.

Authors:  B I Davies; F P Maesen
Journal:  J Antimicrob Chemother       Date:  1986-09       Impact factor: 5.790

3.  Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.

Authors:  G Ruckdeschel; W Ehret; A Ahl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

4.  Antimycoplasmal activity of ofloxacin (DL-8280).

Authors:  Y Osada; H Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Pefloxacin in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

6.  In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.

Authors:  T Kumada; H C Neu
Journal:  J Antimicrob Chemother       Date:  1985-11       Impact factor: 5.790

7.  Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.

Authors:  T Kalager; A Digranes; T Bergan; T Rolstad
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

8.  The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

9.  Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; C Baur
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

10.  In-vitro activity of newer quinolones against aerobic bacteria.

Authors:  R Auckenthaler; M Michéa-Hamzehpour; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  4 in total

Review 1.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

2.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 3.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 4.  Haemophilus influenzae type b conjugate vaccines.

Authors:  Dominic F Kelly; E Richard Moxon; Andrew J Pollard
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.